Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.


TSXV:HEM - Post by User

Bullboard Posts
Comment by duskwon Aug 10, 2010 9:15am
237 Views
Post# 17336726

RE: RE: Q2

RE: RE: Q2

The fact that their growing is good ... but they really need to learn how to make money! Expenses are just too high.. margins are too low. I think the solution is to be acquired and benefit from some economies of scale and the marketting engine behind a larger company. The problem as I see it is if the growth rate doesn't increase the company is just too small to sustain a profitable business with this model.

I think if the Earthworks and other ventures do succeed and the new products gain enough traction the company may be able to hit a critical mass in terms of profitability again. But the shorter term solution is to sell the company. An acquirer can eliminate millions in executive compensation, manufacturing overhead due to scale, R&D to some extent, and perhaps extend the marketting reach, co-market with existing products, leverage technology and patents, and so forth.

IMO, there is some value is a company that is able to generate revenue in the order of $60-$70 million US, no debt, decent technology. But again, at some point it has to come down to making money.

Bullboard Posts